



(51) International Patent Classification:

C07K 14/47 (2006.01) C12N 15/86 (2006.01)
C07K 14/54 (2006.01)

(21) International Application Number:

PCT/US2019/022985

(22) International Filing Date:

19 March 2019 (19.03.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/645,022 19 March 2018 (19.03.2018) US
62/803,887 11 February 2019 (11.02.2019) US

(71) Applicant: **MULTIVIR INC.** [US/US]; 909 Fannin, Site 2100, 2 Houston Center, Houston, TX 77010-1028 (US).

(72) Inventors: **SOBOL, Robert, E.**; c/o MULTIVIR INC., 909 Fannin, Site 2100, 2 Houston Center, Houston, TX 77010-1028 (US). **MENANDER, Kerstin, B.**; c/o MULTIVIR INC., 909 Fannin, Site 2100, 2 Houston Center, Houston, TX 77010-1028 (US). **WIEDERHOLD, Dora**; c/o MULTIVIR INC., 909 Fannin, Site 2100, 2 Houston Center, Houston, TX 77010-1028 (US). **CHADA, Sunil**; C/

o MULTIVIR INC., 909 Fannin, Site 2100, 2 Houston Center, Houston, TX 77010-1028 (US).

(74) Agent: **MANN, Monica**; Parker Highlander PLLC, 1120 So. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS AND COMPOSITIONS COMPRISING TUMOR SUPPRESSOR GENE THERAPY AND CD122/CD132 AGONISTS FOR THE TREATMENT OF CANCER




FIG. 1

(57) Abstract: Provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one CD 122/CD 132 agonist, at least one immune checkpoint inhibitor and a viral composition comprising one or more viruses engineered to overexpress a tumor suppressor gene and/or an adenoviral death protein. Also provided herein are methods and compositions for treating cancer in an individual comprising administering to the individual an effective amount of at least one oncolytic viral composition and at least one CD122/CD132 agonist and at least one immune checkpoint inhibitor. Also provided herein are methods of enhancing anti-tumor efficacy by administering the agents described above in combination with other cancer therapies. In highly aggressive forms of cancer, known to be generally resistant to immune therapies, these treatments unexpectedly resulted in complete tumor remissions and curative outcomes.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

12 March 2020 (12.03.2020)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2019/022985

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(8) - C07K 14/47; C07K 14/54; C12N 15/86 (2020.01)
 CPC - C07K 14/4746; C07K 14/5443; C07K 14/55; C12N 15/86 (2020.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 424/85.2; 424/93.2; 514/19.3 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2017/079746 A2 (MULTIVIR INC.) 11 May 2017 (11.05.2017) entire document	1-118
Y	US 2017/0044229 A1 (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY et al) 16 February 2017 (16.02.2017) entire document	1-118
Y	US 2017/0151310 A1 (NOVARTIS AG et al) 01 June 2017 (01.06.2017) entire document	6
Y	EP 2522726 A1 (FUNDACIÓ PRIVADA CENTRE DE REGULACIÓ GENÒMICA (CRG)) 14 November 2012 (14.11.2012) entire document	20-22
Y	US 2015/0072988 A1 (THE JOHNS HOPKINS UNIVERSITY) 12 March 2015 (12.03.2015) entire document	49, 114

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

15 January 2020

Date of mailing of the international search report

05 FEB 2020

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, VA 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Blaine R. Copenheaver

PCT Helpdesk: 571-272-4300
 PCT OSP: 571-272-7774